Quick Answer: What Does Prostate Cancer Metastasis Mean?
Prostate cancer metastasis means that prostate-cancer cells have spread beyond the prostate and nearby tissues to a distant lymph node, bone or another organ. The new tumor is still prostate cancer—not bone, liver or lung cancer—even when it grows in one of those locations.
Bone and lymph nodes are the most frequent sites. Some men have no symptoms when metastases are found on a scan; others develop persistent bone pain, weakness, fatigue, weight loss or problems caused by pressure on nerves or organs.
Metastatic prostate cancer is usually treated as a whole-body disease. Androgen-deprivation therapy (ADT) remains a foundation, but ADT alone is no longer sufficient for most fit men. It is commonly combined with an androgen-receptor pathway medicine, chemotherapy or another treatment chosen according to previous therapy, disease volume, symptoms, scan findings and tumor genetics.
Although distant metastatic prostate cancer is generally not considered routinely curable, it is treatable. Modern combinations can control it, relieve symptoms and help many patients live longer.
What Is Prostate Cancer Metastasis?
Metastasis is a biological process in which cancer cells leave the original prostate tumor, travel through lymphatic channels or the bloodstream and establish tumors elsewhere in the body.
If prostate cancer reaches a bone, the cells in that lesion still have the characteristics of prostate cancer. Doctors therefore treat it as metastatic prostate cancer, not as a new primary bone cancer.
Metastatic disease may be discovered in two main situations:
- De novo metastatic disease: distant spread is already present when prostate cancer is first diagnosed.
- Metastatic recurrence: metastases appear after earlier treatment such as prostate surgery or radiation.
This distinction matters because the amount and timing of prior treatment can influence the next treatment choice.
Is metastatic prostate cancer always Stage 4?
Distant metastasis is classified as M1 and Stage IVB. Regional pelvic lymph-node involvement without distant spread is N1/M0 and is classified as Stage IVA. Locally advanced cancer can extend just outside the prostate without being distantly metastatic.
For the full relationship between TNM, PSA, Grade Group and stage, read our prostate cancer stages guide.
Where Does Prostate Cancer Commonly Spread?
Prostate cancer has characteristic patterns of spread, but each patient is different. A scan may show one lesion, several lesions or more extensive disease.
| Site | What it may cause | Important points |
|---|---|---|
| Bone | Persistent pain, reduced mobility, fracture, vertebral collapse, high alkaline phosphatase or spinal cord compression | The spine, pelvis, ribs and upper parts of the long bones are frequent locations. A bone lesion may initially cause no symptoms. |
| Lymph nodes | Often no symptoms; extensive disease may contribute to leg or genital swelling or pressure on nearby structures | Pelvic nodes are regional (N1). Nodes outside the regional pelvis are distant metastases (M1a). |
| Liver | Fatigue, loss of appetite, weight loss, abdominal discomfort or abnormal liver tests | Visceral metastasis can reflect more aggressive biology and may require reconsideration of tumor type and treatment. |
| Lung or pleura | Sometimes no symptoms; cough, breathlessness or chest discomfort can occur | Small lung lesions may be detected only on imaging. |
| Other sites | Symptoms depend on the organ affected | Brain and other organ metastases are less common, but new neurological symptoms require prompt assessment. |
What Are the Symptoms of Metastatic Prostate Cancer?
Metastatic prostate cancer does not always cause symptoms. Increasingly sensitive scans can detect small metastases before a patient feels unwell.
When symptoms occur, they may include:
- persistent pain in the back, hips, pelvis, ribs or other bones;
- pain that is worsening, disturbs sleep or is not explained by an injury;
- difficulty walking, weakness, numbness or tingling;
- fractures after minor trauma;
- fatigue, pallor, breathlessness or dizziness from anemia;
- reduced appetite or unexplained weight loss;
- urinary obstruction, blood in the urine or kidney problems;
- leg or genital swelling from lymphatic or venous obstruction;
- cough or shortness of breath when the lungs or pleura are involved; or
- abdominal discomfort, jaundice or abnormal liver tests when there is substantial liver involvement.
These symptoms are not specific to cancer. Arthritis, a slipped disc, anemia, infection and many other conditions can produce similar problems. What matters is reporting a new, persistent or worsening symptom to the oncology team rather than assuming it is simply part of aging.
Our separate guide explains advanced prostate cancer symptoms in more detail.
Metastatic spinal cord compression is an emergency
Metastases in the vertebrae can weaken bone or press on the spinal cord. Early treatment can reduce the risk of permanent nerve damage.
Seek urgent assessment for:
- new severe back or neck pain;
- pain wrapping around the chest or abdomen;
- pain made worse by coughing, sneezing or straining;
- new weakness or heaviness in the legs;
- numbness, altered sensation or difficulty walking; or
- new loss of bladder or bowel control.
Guidelines recommend urgent imaging—usually MRI—and immediate specialist management when spinal cord compression is suspected.
How Do Doctors Check Whether Prostate Cancer Has Spread?
No single test answers every question. Doctors combine symptoms, examination, blood tests, pathology and imaging.
PSA and other blood tests
PSA is useful for detecting a trend and monitoring many prostate cancers, but it cannot confirm metastasis by itself. Other tests may include:
- complete blood count to look for anemia or bone-marrow effects;
- kidney and liver function;
- alkaline phosphatase, which can rise with active bone disease;
- calcium; and
- testosterone in men receiving ADT.
PSMA PET/CT
PSMA PET/CT uses a tracer that binds to prostate-specific membrane antigen expressed by many prostate-cancer cells. It can identify nodal, bone and organ disease that is too small to appear on conventional scans.
It is highly useful, but it is not infallible. Some prostate cancers express little PSMA, and inflammation or other conditions can occasionally produce uptake. Results must be interpreted in the complete clinical context.
CT, MRI and bone scan
- CT assesses lymph nodes, organs and other soft tissues.
- MRI provides detailed views of the prostate, pelvis, spine, brain or another symptomatic region.
- Bone scintigraphy identifies areas of increased bone activity and remains an important conventional staging test.
Many major treatment trials defined low- and high-volume disease using conventional CT and bone scans. A patient with tiny lesions visible only on PSMA PET may not fit perfectly into the same evidence categories, so treatment decisions require careful specialist interpretation.
Biopsy and genetic testing
A biopsy of a metastatic site may be considered when the diagnosis is uncertain, the pattern is unusual, or doctors suspect that the cancer has changed into a more aggressive variant such as treatment-emergent neuroendocrine prostate cancer.
Men with metastatic prostate cancer should also discuss:
- germline testing, which looks for inherited variants and may have implications for relatives; and
- somatic tumor testing, performed on tumor tissue or circulating tumor DNA to identify changes that may guide targeted treatment.
Relevant findings can include BRCA1/2 and other homologous-recombination repair alterations, mismatch-repair deficiency or microsatellite instability, and—in selected settings—PTEN-pathway changes.
What Do M1a, M1b and M1c Mean?
| Category | Meaning |
|---|---|
| M1a | Metastasis to non-regional lymph node(s). |
| M1b | Metastasis to bone(s). |
| M1c | Metastasis to another distant site, such as the liver or lung, with or without bone disease. |
The M category describes location, but treatment also depends on disease volume, timing, symptoms and biological behavior.
Low-volume, high-volume and oligometastatic disease
Low-volume and high-volume are trial-based classifications used to help select therapy. One commonly used definition—developed in the CHAARTED trial—classifies high-volume disease as visceral metastasis and/or at least four bone metastases, with at least one outside the vertebral bodies and pelvis.
Oligometastatic generally means only a small number of visible metastatic sites, but studies do not all use the same cutoff. Stereotactic radiation to individual metastases is promising for carefully selected patients, particularly in recurrence, but it should not automatically replace proven systemic treatment. The 2026 EAU guideline still regards metastasis-directed therapy for M1 disease as investigational outside a clinical trial or well-designed prospective study.
Hormone-Sensitive and Castration-Resistant Metastatic Disease
These terms describe how the cancer behaves in relation to testosterone-lowering treatment.
Metastatic hormone-sensitive prostate cancer
Metastatic hormone-sensitive prostate cancer (mHSPC), also called metastatic castration-sensitive prostate cancer, still responds to treatment that lowers testosterone or blocks androgen signaling. The U.S. FDA now also uses the term metastatic androgen pathway modulation-naïve or -sensitive prostate cancer (mAPMN/S).
Metastatic castration-resistant prostate cancer
Metastatic castration-resistant prostate cancer (mCRPC) is cancer that progresses despite testosterone being maintained at a castrate level. Progression may be seen in PSA, scans or clear clinical findings.
Castration-resistant does not mean treatment-resistant. ADT is usually continued, and several additional treatments can still control the cancer.
How Is Metastatic Prostate Cancer Treated?
Treatment should be planned by a multidisciplinary team whenever possible. Important factors include:
- whether the disease is hormone-sensitive or castration-resistant;
- whether metastasis was present at diagnosis or appeared after prior local treatment;
- low- versus high-volume disease;
- bone-only, nodal or visceral spread;
- symptoms and urgency;
- prior medicines and response duration;
- PSMA expression and tumor genetics;
- heart, liver, kidney, nerve and bone health;
- fitness for chemotherapy; and
- patient priorities and local treatment availability.
1. Androgen-deprivation therapy remains the foundation
Most prostate-cancer cells depend on androgen signaling. ADT reduces testosterone through injections, tablets that act on the hormonal pathway, or surgical removal of the testes.
For most fit men with newly diagnosed M1 disease, ADT alone is no longer the preferred standard. Current guidelines recommend combining it with an effective additional treatment unless there is a contraindication or the patient cannot tolerate intensification.
Read our detailed explanation of hormone therapy and ADT for prostate cancer.
2. Androgen-receptor pathway inhibitors
Medicines such as abiraterone plus a corticosteroid, apalutamide, enzalutamide or darolutamide can be combined with ADT in appropriate patients. These combinations improve outcomes compared with ADT alone, but their risks differ.
Selection should consider blood pressure, cardiovascular disease, falls, seizures, liver function, medication interactions and whether chemotherapy is also planned.
3. Chemotherapy and triplet treatment
Docetaxel can be used early in metastatic hormone-sensitive disease, particularly as part of a triplet regimen consisting of ADT, docetaxel and either darolutamide or abiraterone in suitable patients. The balance depends on disease volume, whether metastasis was present at first diagnosis and the patient’s fitness.
Docetaxel and later cabazitaxel also have roles in mCRPC. Age alone does not decide chemotherapy suitability; functional status, other illnesses, blood counts and patient preference matter more.
4. Radiation to the prostate in selected newly diagnosed patients
Radiotherapy to the prostate can improve outcomes for selected men whose first presentation is metastatic but whose disease volume is low on conventional imaging. It is added to systemic treatment; it is not a replacement for it.
By contrast, prostate surgery is not standard treatment for widespread M1 disease outside clinical trials. This is because removing the primary tumor does not remove established cancer throughout the body—not because surgery causes cancer to spread.
Learn more about radiation therapy for prostate cancer.
5. PSMA-targeted radioligand therapy
Lutetium-177 vipivotide tetraxetan (Pluvicto) delivers radiation to PSMA-expressing cancer cells. A PSMA PET scan is used to confirm suitable tumor uptake.
Possible risks include radiation exposure, reduced blood-cell counts, kidney toxicity and infertility. This is not the same as ordinary external-beam radiation.
6. Biomarker-directed and targeted treatment
PARP inhibitors may be used alone or with another medicine in selected advanced cancers with BRCA or other homologous-recombination repair alterations. The exact approved mutation, combination and disease setting vary between regulatory regions.
Recent U.S. examples show why early testing matters. The FDA approved niraparib with abiraterone and prednisone for BRCA2-mutated metastatic castration-sensitive disease in December 2025, and capivasertib with abiraterone and prednisone for PTEN-deficient metastatic androgen pathway modulation-naïve or -sensitive disease in June 2026. These are biomarker-selected treatments, not options for every patient.
Pembrolizumab may be considered for the uncommon tumor with a qualifying biomarker such as mismatch-repair deficiency or high microsatellite instability. These treatments are reasons to obtain appropriate molecular testing rather than choosing therapy from PSA alone.
7. Radium-223
Radium-223 is an alpha-emitting radiopharmaceutical used in selected men with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases. It targets areas of increased bone turnover. It is not a treatment for liver or lung metastases, and safe combinations require specialist review.
8. Immunotherapy
Sipuleucel-T is a cellular immunotherapy available in some countries for selected men with asymptomatic or minimally symptomatic mCRPC. Checkpoint immunotherapy is not routinely effective for unselected prostate cancer, but it can help the small biomarker-defined group described above.
| Treatment approach | Possible role | What must be considered |
|---|---|---|
| ADT | Foundation of systemic treatment | Hot flushes, sexual effects, fatigue, metabolic and cardiovascular health, muscle and bone loss |
| AR-pathway medicine | Common intensification with ADT; also used in selected resistant disease | Prior therapy, heart and liver health, blood pressure, falls, interactions and medicine-specific risks |
| Docetaxel/cabazitaxel | Chemotherapy for suitable hormone-sensitive or resistant disease settings | Fitness, infection risk, blood counts, neuropathy and prior treatment |
| Prostate radiotherapy | Selected newly diagnosed low-volume metastatic disease | Systemic therapy remains necessary; urinary and bowel risks |
| Local radiation to a metastasis | Pain relief, prevention/treatment of complications; selected oligometastatic strategies | Goal may be symptom control; MDT remains investigational in some settings |
| PARP-directed treatment | Selected tumors with qualifying DNA-repair alterations | Exact mutation, prior therapy, anemia and regional approval |
| PSMA radioligand therapy | Selected PSMA-positive metastatic disease | PSMA PET findings, marrow and kidney function, prior therapy and local approval |
| Radium-223 | Selected symptomatic bone-predominant mCRPC without visceral disease | Blood counts, fracture protection, other systemic therapy and absence of visceral metastasis |
For a broader overview, see our current prostate cancer treatment guide.
Treating Bone Metastases and Protecting Bone Health
Bone care has two related but different goals:
- treating cancer and complications within bone; and
- preventing osteoporosis and fractures caused or worsened by long-term ADT.
The care plan may include:
- prompt pain assessment and appropriate analgesia;
- external-beam radiotherapy to a painful or high-risk lesion;
- orthopedic or spinal review for an impending or existing fracture;
- urgent steroids, MRI and surgical/radiation assessment for suspected spinal cord compression;
- DEXA scanning and fracture-risk assessment when long-term ADT begins;
- weight-bearing and resistance exercise when medically safe;
- adequate—not excessive—calcium and vitamin D; and
- denosumab or a bisphosphonate in appropriate osteoporosis or metastatic CRPC settings.
Doses and indications for osteoporosis prevention are not identical to those used to prevent skeletal complications from metastatic cancer. Calcium must be monitored with denosumab or bisphosphonate treatment, and dental assessment may be needed because osteonecrosis of the jaw is an uncommon but serious risk.
Supportive and Palliative Care Should Start Early
Palliative care does not mean stopping cancer treatment. It focuses on symptoms, function and quality of life and can be provided at the same time as life-prolonging therapy.
Support may address:
- pain and mobility;
- fatigue and sleep;
- hot flushes and sexual health;
- muscle and bone loss;
- nutrition and weight change;
- urinary or bowel problems;
- anxiety, depression and uncertainty;
- work, finances and family communication; and
- future care preferences.
Exercise and nutrition can support strength and treatment tolerance, but no diet, vitamin or herbal product has been proven to cure metastatic prostate cancer. Review supplements with the oncology team because interactions are possible. See our evidence review of alternative and complementary prostate cancer treatments.
How Is Metastatic Prostate Cancer Monitored?
Monitoring should measure the cancer, the treatment and the patient’s day-to-day condition.
Follow-up may include:
- symptoms, pain, mobility and quality of life;
- PSA trend;
- testosterone while receiving ADT;
- complete blood count;
- kidney and liver function;
- alkaline phosphatase and calcium;
- blood pressure, glucose, cholesterol and cardiovascular risk;
- bone density where indicated; and
- repeat CT, MRI, bone scan or PET-based imaging when clinically appropriate.
PSA alone is not enough in advanced castration-resistant disease. Scans, symptoms and blood tests must also be considered because radiographic or visceral progression can occasionally occur without a parallel PSA rise.
Can Metastatic Prostate Cancer Be Cured?
Distant metastatic prostate cancer is generally considered treatable rather than routinely curable. Treatment can shrink or stabilize cancer, lower PSA, relieve pain and prolong life. Some men experience control for years, while others have biologically aggressive disease that progresses more quickly.
Prognosis is influenced by:
- how much cancer is present and where it has spread;
- whether it is hormone-sensitive or castration-resistant;
- response to the first course of systemic treatment;
- Grade Group and tumor biology;
- molecular findings;
- presence of liver or other visceral metastases;
- pain, anemia and general fitness; and
- which effective treatments are available and safe for the individual.
Population survival statistics cannot predict one person’s future. They combine patients of different ages, disease burdens, treatment eras and health conditions. The treating oncologist can provide a more meaningful estimate using the complete clinical picture.
For more context, read Can prostate cancer be cured? and our dedicated Stage 4 prostate cancer guide.
Questions to Ask the Oncology Team
- Where has my prostate cancer spread, and which scan showed it?
- Is my cancer M1a, M1b or M1c?
- Is it hormone-sensitive or castration-resistant?
- Is the disease considered low volume, high volume or oligometastatic?
- What is the goal of treatment in my situation?
- Why are you recommending this combination instead of ADT alone?
- Should my prostate itself receive radiation?
- Do I need germline and tumor genomic testing?
- Is my cancer PSMA-positive, and could radioligand therapy ever be appropriate?
- How will treatment affect my heart, bones, muscles, sexual health and daily function?
- Which symptoms require an urgent call or emergency assessment?
- How will we know whether treatment is working?
Frequently Asked Questions
Does a high PSA mean prostate cancer has metastasized?
No. A high or rising PSA increases concern but does not prove distant spread. Imaging is needed, and PSA must be interpreted alongside Grade Group, previous treatment and the rate of change.
Is prostate cancer in the bone the same as bone cancer?
No. It remains prostate cancer because the metastatic cells originated in the prostate. Treatment is selected for metastatic prostate cancer.
Can prostate surgery cause cancer to spread?
No. Surgery does not release or accelerate prostate cancer. Radical prostatectomy is usually not standard for widespread M1 disease because it cannot remove cancer already established elsewhere.
Can a person have metastatic prostate cancer without pain?
Yes. Small nodal or bone metastases may cause no symptoms and may be found only during staging or follow-up imaging.
Does a lower PSA always mean the metastases are gone?
No. A PSA fall is often encouraging, but response assessment may also require imaging, symptoms and other blood tests. Some cancer variants produce relatively little PSA.
Can metastatic prostate cancer go into remission?
Treatment can produce a deep response in which PSA falls substantially and visible disease shrinks or becomes difficult to detect. Doctors usually describe this as response or disease control rather than assuming every metastatic cell has been eliminated.
When a patient hears the word “metastasis,” the diagnosis can feel immediately overwhelming. I encourage families to turn that one frightening word into a set of specific questions: Where is the disease? How much is present? Is it hormone-sensitive? What did the scan show? Which biomarkers have been tested?
Those details matter because metastatic prostate cancer is not one uniform condition. A man with a small number of hormone-sensitive bone lesions is in a different situation from someone whose cancer has progressed through several treatments or developed liver metastases.
I would also not judge response by PSA alone. PSA, imaging, symptoms, testosterone and treatment side effects all belong in the same conversation. The aim is not only to control the cancer, but to protect mobility, bone strength, cardiovascular health and quality of life for as long as possible.
Finally, please treat new neurological symptoms as urgent. New back pain with weakness, numbness, walking difficulty or bladder/bowel change should never wait for the next scheduled appointment.
Medical References
- European Association of Urology. 2026 Guidelines on Prostate Cancer: Treatment—systemic combination therapy, prostate radiotherapy in low-volume disease, bone care, spinal cord compression and mCRPC options.
- European Association of Urology. 2026 Guidelines: Diagnostic Evaluation—PSMA PET/CT and staging evaluation.
- European Association of Urology. 2026 Guidelines: Follow-up—imaging and monitoring principles.
- National Cancer Institute. Prostate Cancer Treatment (PDQ), Health Professional Version—treatment of metastatic prostate cancer.
- National Cancer Institute. Metastatic Cancer: When Cancer Spreads—definition, treatment goals and supportive care.
- U.S. Food and Drug Administration. July 31, 2026 approval of lutetium Lu 177 vipivotide tetraxetan with ARPI therapy for PSMA-positive mAPMN/S prostate cancer.
- U.S. Food and Drug Administration. Expanded Pluvicto indication for PSMA-positive mCRPC, March 2025.
- U.S. Food and Drug Administration. Oncology approval notifications—2025–2026 biomarker-selected prostate-cancer approvals, including BRCA2- and PTEN-defined treatment settings.
Last evidence update: September 2026.
Medical information notice: This article provides general education and cannot select treatment for an individual patient. Metastatic prostate cancer requires specialist assessment using complete pathology, imaging, previous treatment, laboratory results, other health conditions and patient preferences. Medicine approvals and access vary by country.